MacroGenics Signs Second Regional Option-Based Deal with Servier
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 10 (Table of Contents)
Published: 1 Oct-2012
DOI: 10.3833/pdr.v2012.i10.1812 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Les Laboratoires Servier has entered into a second regional option-based deal with MacroGenics, this time to use the company’s DART™ (dual-affinity re-targeting) platform to develop and commercialise bispecific antibodies against three undisclosed cancer targets...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018